Spectinomycin (hydrochloride hydrate)
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Spectinomycin is an aminocyclitol antibiotic produced by S. spectabilis with activity against gram-negative bacterial species. Spectinomycin has been used for the treatment of gonorrhea, where it inhibits microbial protein synthesis by binding to the 30S ribosomal subunit, protects the N‐7 position of E. coli 16S rRNA residue G1064 from methylation by dimethyl sulfate. Binding of spectinomycin at this location is thought to stabilize helix 34, inhibiting the binding of elongation factor G, thereby blocking translocation of peptidyl‐tRNAs from the ribosomal A site to the P site [1].
Spectinomycin selectively inhibited protein synthesis in cells and in extracts of E. coli. Mutations to high-level resistance to this antibiotic map close to the streptomycin locus, and the site of action of spectinomycin, like that of streptomycin, is the 30S ribosomal subunit, as shown by experiments with reconstituted 70S ribosomes containing subunits from sensitive and from resistant ribosomes [2].
References:
[1] Zimmerman J M, Maher L J. In vivo selection of spectinomycin‐binding RNAs[J]. Nucleic acids research, 2002, 30(24): 5425-5435.
[2] Davies J, Anderson P, Davis B D. Inhibition of protein synthesis by spectinomycin[J]. Science, 1965, 149(3688): 1096-1098.
Storage | Store at -20°C |
M.Wt | 495.4 |
Cas No. | 22189-32-8 |
Formula | C14H24N2O7·2HCl [5H2O] |
Solubility | ≥49.5 mg/mL in H2O; ≥3.61 mg/mL in EtOH with gentle warming and ultrasonic; ≥92 mg/mL in DMSO |
Chemical Name | (5aR,9aR,10aS)-decahydro-4aR,7S,9S-trihydroxy-2R-methyl-6S,8R-bis(methylamino)-4H-pyrano[3-b][1,4]benzodioxin-4-one, dihydrochloride pentahydrate |
SDF | Download SDF |
Canonical SMILES | [H][C@@]12[C@@](C(C[C@@H](C)O2)=O)(O)O[C@]3([H])[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@@]3([H])O1.Cl.Cl.O.O.O.O.O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Cell experiment:[1] | |
Cell lines |
Escherichia coli B |
Reaction Conditions |
50 μg/mL spectinomycin |
Applications |
When added to an exponentially growing culture, spectinomycin (50 μg/mL) rapidly and reversibly inhibited growth of Escherichia coli B. Amino acid incorporation was slowed immediately but RNA synthesis continued. |
Animal experiment:[2] | |
Animal models |
Male Sprague-Dawley rats, 200 ~ 225 g |
Dosage form |
10 mg/kg Administered intravenously (IV) |
Applications |
Following IV administration, approximately 55% of the drug was excreted into the urine in unchanged form. Spectinomycin at the dose of 10 mg/kg showed a peak plasma concentration of 37.8 μg/mL and a systemic exposure (area-under the curve AUC0-∞) of 15.7 μg h/mL. |
Note |
The technical data provided above is for reference only. |
References: 1. Davies J, Anderson P, Davis BD. Inhibition of protein synthesis by spectinomycin. Science, 1965, 149(3688): 1096-1098. 2. Madhura DB, Lee R, Meibohm B. Pharmacokinetic profile of spectinomycin in rats. Pharmazie, 2013, 68(8): 675-676. |
质量控制和MSDS
- 批次: